Cardiac hybrid imaging by Gaemperli, Oliver et al.
REVIEW
Imaging
Cardiac hybrid imaging
Oliver Gaemperli 1*, Frank M. Bengel2,3, and Philipp A. Kaufmann 1
1Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, CH-8091 Zurich, Switzerland; 2Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and
Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA; and 3Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany
Received 4 January 2011; revised 1 February 2011; accepted 9 February 2011; online publish-ahead-of-print 15 March 2011
This paper was guest edited by Jeroen J. Bax, Leiden University Medical Center, The Netherlands
Computed tomography coronary angiography (CTCA) and myocardial perfusion imaging techniques (single photon emission computed tom-
ography, SPECT, or positron emission tomography, PET) are established non-invasive modalities for the diagnosis of coronary artery disease
(CAD). Cardiac hybrid imaging consists of the combination (or ‘fusion’) of both modalities and allows obtaining complementary morpho-
logical (coronary anatomy, stenoses) and functional (myocardial perfusion) information in a single setting. However, hybrid cardiac
imaging has also generated controversy with regard to which patients should undergo such integrated examinations for clinical effectiveness
and minimization of costs and radiation dose. The feasibility and clinical value of hybrid imaging has been documented in small cohort studies
and selected series of patients. Hybrid imaging appears to offer superior diagnostic and prognostic information compared with stand-alone or
side-by-side interpretation of data sets. Particularly in patients with multivessel disease, the hybrid approach allows identification of flow-
limiting coronary lesions and thereby provides useful information for the planning of revascularization procedures. Furthermore, integration
of the detailed anatomical information from CTCA with the high molecular sensitivity of SPECT and PET may be useful to evaluate targeted
molecular and cellular abnormalities in the future. While currently still restricted to specialized cardiac centres, the ongoing efforts to reduce
radiation exposure and the increasing clinical interest will further pave the way for an increasing use of cardiac hybrid imaging in clinical
practice.
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Coronary morphology and
function—two sides of the same
coin
Since the introduction of invasive coronary angiography (ICA) pro-
cedures by Sones et al.1 in 1959, the diagnosis and management of
coronary artery disease (CAD) has been dominated by the search
for luminal narrowing and the evaluation of stenosis severity
observed on angiographic films. Notwithstanding the great value
of ICA over the past decades, the evaluation of coronary ‘luminol-
ogy’ only addresses one side of the coin and fails to accurately
assess the effects of luminal narrowing on myocardial blood
flow. A number of landmark studies have consistently demon-
strated that the angiographic severity of coronary lesions is a
poor predictor of its haemodynamic relevance, and have led to a
paradigm shift in CAD care, emphasizing the role of myocardial
ischaemia.2,3 In 1984, White et al.4 observed a very weak corre-
lation of stenosis severity with hyperaemic coronary blood flow
measured by Doppler technique in patients undergoing coronary
artery bypass graft (CABG) surgery. Ten years later, Uren demon-
strated that coronary flow reserve [measured with positron emis-
sion tomography (PET)] declines with increasing stenosis severity,
reaching unity at stenoses of 80% or more.5 This relationship,
however, was governed by a large scatter proving that the same
degree of luminal narrowing may have varying pathophysiological
effects in different individuals. Recent studies using fractional flow
reserve (FFR) have shown that among stenoses of 50–90%, angio-
graphy is inaccurate in determining the haemodynamic relevance of
a given lesion.6 Similarly, a comparison study of computed tom-
ography coronary angiography (CTCA) and myocardial perfusion
single photon emission tomography (SPECT) has shown that
only 32% of significant coronary stenoses (≥50%) are associated
with perfusion defects on SPECT (Figure 1).7
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These academic observations have been confirmed by clinical
studies supporting the importance of ischaemia testing for the
care of stable CAD patients. The two largest randomized trials,
the COURAGE and BARI-2D trials, both including patients with
angiographically documented CAD, have failed to demonstrate a
prognostic benefit of revascularization strategies compared with
contemporary medical therapies.8,9 A retrospective observation
in .10 000 patients, however, suggests that stable CAD patients
may benefit from revascularization procedures in the presence
of myocardial ischaemia involving 10% or more of the left ventri-
cular myocardium.10 The prospective nuclear substudy of the
COURAGE trial, albeit slightly underpowered to detect significant
differences in cardiovascular outcomes, showed that percutaneous
coronary interventions (PCIs) were more effective in reducing
myocardial ischaemia than optimal medical treatment alone
(22.7 vs. 20.5%), and that the reduction in ischaemic burden
was correlated with the prognosis of the patient.11 In the random-
ized prospective FAME trial, measurement of FFR prior to PCI
resulted in a reduction in the number of implanted stents (1.9+
1.3 vs. 2.7+ 1.2) and in a significant 35% reduction in overall mor-
tality and myocardial infarction.12
These data highlight the importance of assessing both sides of
the coin, the presence of coronary lesions and their haemo-
dynamic relevance, in order to offer stable CAD patients the
most appropriate treatment strategy. In fact, the recently published
joint revascularisation guidelines by the European Society of Cardi-
ology (ESC) and the European Association of Cardiothoracic Sur-
geons (EACTS) give a class I recommendation (level of evidence A)
for assessing myocardial ischaemia prior to any revascularization
procedure.13 The tremendous technological evolution achieved
in non-invasive imaging techniques over the last decades, including
CTCA, SPECT, PET, or stress cardiac magnetic resonance (CMR)
have provided cardiologists with a large non-invasive armamentar-
ium for CAD assessment. These techniques coupled with the
development of dedicated image fusion software packages to
merge data sets from different modalities have paved the way for
hybrid imaging.14 In nuclear imaging, these developments have
been further supported by the tremendous success of hybrid
whole body PET/CT imaging in oncology. First pioneering attempts
of cardiac image fusion between myocardial perfusion imaging
(MPI) with SPECT and coronary arterial tree derived from ICA
were promising but their widespread use was precluded by
issues of the invasiveness of coronary angiography, the lack of dedi-
cated fusion software, and often tedious and time-consuming
image processing.15,16 Today, hardware and software requirements
for hybrid imaging are met by most manufacturers which provide
simple platforms for introducing hybrid imaging into the clinical
practice.
Computed tomography coronary
angiography and myocardial
perfusion imaging—suited for
hybrid imaging?
Myocardial perfusion imaging
In the last three decades, myocardial perfusion SPECT has estab-
lished itself as an excellent non-invasive method for the diagnosis
of CAD with flow-limiting lesions with a sensitivity and specificity
of 87–89% and 73–75%, respectively, depending on the choice of
radionuclide and stress modality.17 Additionally, SPECT has proved
very useful for risk stratification and a wealth of data is available
indicating its independent prognostic value in different clinical set-
tings such as stable CAD, prior to non-cardiac surgery, after cor-
onary revascularisation, and in acute coronary syndromes. Most
importantly, in stable patients, a normal perfusion scan is associ-
ated with an excellent mid-term prognosis (risk of death or non-
fatal MI ,1% per year) even in the presence of angiographically
documented CAD.18
Nonetheless, by nature, SPECT can only detect coronary lesions
that induce perfusion defects, but does not exclude the presence
of subclinical non-obstructive coronary atherosclerosis.19,20
However, 70% of plaque ruptures leading to myocardial infarc-
tions occur in lesions that are non-obstructive and therefore
may be missed by SPECT.21 Indeed, large longitudinal studies in
patients undergoing myocardial perfusion SPECT, have shown
that a substantial proportion of patients suffering cardiac events
(43% of patients suffering an acute MI and 31% succumbing to
cardiac death) have normal or near-normal perfusion scans prior
to their event.22,23 Additionally, in patients with multivessel
CAD, SPECT may underestimate the true extent of disease,
since likelihood of detection is highest with culprit lesions but
lower with other milder lesions.24– 26 Balanced reduction in myo-
cardial hyperaemic blood flow is probably rather rare but it may
explain paradoxical underestimation of clinical risk in high-risk
cohorts with a normal or near-normal SPECT. Finally, particularly
in obese subjects, SPECT is prone to false-positive results due to
non-uniform photon attenuation.27
Positron emission tomography has higher spatial and temporal
resolution than SPECT and, due to more robust methods of
Figure 1 Functionally relevant coronary artery disease: com-
parison of 64-slice computed tomography coronary angiography
with myocardial perfusion single photon emission computed
tomography. While almost all coronary arteries without obstruc-
tive lesions were associated with a normal perfusion (left pie
chart), only 32% of significant coronary stenoses (≥50%)
induced a perfusion defect on SINGLE photon emission computed
tomography (right pie chart). Adapted from Gaemperli et al.7
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attenuation correction, allows quantification of resting and hyper-
aemic regional myocardial perfusion. Quantification of regional
perfusion appears to be useful in patients with diffuse CAD or
balanced disease where the relative assessment of myocardial
perfusion by SPECT may fail in uncovering true perfusion
changes.25 A recent review reports a high weighted sensitivity
and specificity of 90 and 89%, respectively, and smaller compari-
sons with SPECT suggest a higher diagnostic accuracy for PET.28
Several series with 82Rb PET reported an incremental contri-
bution to prognostication by the addition of measurement of
changes in the ejection fraction, improving the identification of
multivessel CAD.29 Clinical circumstances in which PET may be
particularly preferable to SPECT include obese patients with
high soft tissue attenuation and patients with a higher pre-test
likelihood of multivessel CAD.
Computed tomography coronary
angiography
On the other hand, CTCA has advanced over the past years as the
most accurate tool for noninvasive coronary angiography. Current
multi-slice devices coupled with improved acquisition protocols
allow robust and reproducible assessment of coronary
morphology with high temporal and spatial resolution at low radi-
ation exposure.30,31 The diagnostic performance of CTCA com-
pared with ICA has been evaluated in over 45 single-centre
studies.32 Recently, three multi-centre studies have demonstrated
the high diagnostic accuracy of 64-slice CTCA with a sensitivity
and specificity of 85–99% and 64–90%, respectively, and very
low rates of non-evaluable scans.33–35 Particularly, the high nega-
tive predictive value (NPV) which is close to 100% has positioned
CTCA as an excellent tool for ruling out the presence of CAD in
patients with low to intermediate pre-test probability.36
Nonetheless, despite its high diagnostic accuracy, CTCA remains
a purely anatomical technique, and very much like ICA, is poor at
predicting the haemodynamic relevance of stenoses.7,19 However,
besides delineation of the coronary lumen, CTCA also allows visu-
alization of the coronary vessel wall, thereby providing valuable
information on the presence of eccentric non-obstructive
plaques as well as plaque size, composition, calcifications, and vas-
cular remodelling.37 Although the clinical significance of these par-
ameters is still under intense investigation, evidence is accumulating
for an incremental prognostic value of detecting non-obstructive
coronary plaques over the presence of coronary stenoses in
stable CAD patients. Van Werkhoven showed that the presence
of non-calcified (so-called soft plaques with presumably high-lipid
Figure 2 Fifty-four-year-old patient with a congenital coronary anomaly consisting of a common origin of all four coronary arteries (left
anterior descending, septal branch (septal), right coronary artery, and left circumfley artery) from the right coronary ostium (A). The invasive
coronary angiography (B) shows selectively the retroaortic course of the left circumflex and collaterals to the occluded right coronary artery
(arrows). On hybrid single photon emission computed tomography/computed tomography imaging (C and D), a fixed perfusion defect can be
appreciated in the territory of the occluded right coronary artery (arrows). The left anterior descending artery runs anterior to the pulmonary
trunk, and the septal branch runs on an interarterial course between pulmonary trunk and ascending aorta to the septal wall.
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content) provided incremental prognostic information over the
presence of obstructive lesions, and clinical variables.38 In a pro-
spective study by Motoyama39, low CT plaque attenuation (,30
Hounsfield units) and positive vessel remodelling were identified
as strong predictors of future acute ischaemic events. These find-
ings support the notion that non-obstructive coronary lesions,
despite having no effect on myocardial perfusion, may harbour
the risk for rupture and subsequent vessel thrombosis. Thus,
CTCA has a complementary role to myocardial perfusion SPECT
and represents an ideal partner modality for hybrid imaging.
Hybrid imaging—nice to have or
truly needed?
The incremental value of hybrid cardiac imaging resides in the
accurate spatial co-localization of myocardial perfusion defects
and subtending coronary arteries (Figure 2). Traditionally, this
integration process is mentally performed by using a standar-
dized myocardial segmentation model that allocates each
segment to one of the three main coronary arteries, thereby
defining standardized myocardial vascular territories.40
However, coronary artery anatomy varies considerably among
individuals, and disagrees with standardized vascular territories
in a significant proportion of patients, particularly in the vascular
territories of the left circumflex (LCX) and right coronary artery
(RCA). In a recent study, Javadi et al.41 compared standardized
myocardial vascular territories with individual coregistered myo-
cardial territories using 82Rb PET/CTCA and found disagreement
in 9% of all segments. Notably, in 72% of all patients, a disagree-
ment in at least one myocardial segment was found. Most fre-
quently, standard right coronary segments were reassigned to
the LCX territory (39% of reassigned segments), and standard
circumflex segments were reassigned to the left anterior des-
cending territory (30%) (Figure 3). The validity of segmental
assignment with hybrid PET/CTCA was tested by comparison
with ex vivo Monastral Blue dye staining in dogs with experimen-
tal coronary stenoses and has yielded an excellent agreement
(kappa 0.80).
Clinical value of hybrid imaging
Table 1 shows a summary of clinical studies evaluating the diag-
nostic performance of cardiac hybrid imaging. The feasibility and
clinical robustness of non-invasive hybrid imaging was first docu-
mented by Namdar et al. in a clinical study involving fusion of
13N–NH3 PET with 4-slice CTCA in 25 patients with CAD.
42
The hybrid PET/CTCA images allowed to identify flow-limiting
coronary lesions which required a revascularization procedure
(as defined by ICA and PET) with a sensitivity, specificity, posi-
tive predictive value (PPV), and NPV of 90, 98, 82, and 99%,
respectively. These encouraging results were confirmed by a
similar study with SPECT/CTCA showing that the hybrid
approach resulted in a significant improvement in specificity
(from 63 to 95%) and PPV (from 31 to 77%) compared with
CTCA alone for detecting flow-limiting coronary stenoses.43 A
similar diagnostic performance was reported by Groves et al.44
Figure 3 Percentages of reassigned myocardial segments after
individual review of hybrid positron emission tomography/com-
puted tomography images. Standardized myocardial assignment
is shown by colour. Most frequently, standard right coronary seg-
ments were reassigned to the left circumflex territory (39% of
reassigned segments), and standard circumflex segments were
reassigned to the left anterior descending territory (30%).
Adapted from Javadi et al.41 with permission of the Society of
Nuclear Medicine.
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Table 1 Diagnostic accuracy of cardiac hybrid imaging (SPECT/CTCA and PET/CTCA) (Vessel-based analysis)
Author Hybrid system n Gold standard (definition of significant CAD) Sens Spec PPV NPV
Namdar et al.42 13N–NH3 PET/4-slice
CTCA
25 Flow-limiting coronary stenoses requiring revascularization
(ICA + PET)
90 98 82 99
Rispler et al.43 SPECT/16-slice CTCA 56 Flow-limiting coronary stenoses (.50% stenosis on
ICA + SPECT pos.)
96 95 77 99
Groves et al.44 82Rb PET/64-slice CTCA 33 .50% stenosis on ICA 88 100 97 99
Sato et al.45 SPECT/64-slice CTCAa 130 .50% stenosis on ICA 94 92 85 97
Kajander
et al.46
15O–H2O PET/64-slice
CTCA
107 Flow-limiting coronary stenosis (.50% stenosis of ICA + FFR) 93 99 96 99
n denotes the number of patients in each study; SPECT, single photon emission computed tomography; CTCA, CT coronary angiography; PET, positron emission tomography;
CAD, coronary artery disease; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; ICA, invasive coronary angiography; FFR, fractional
flow reserve.
aHybrid SPECT/CTCA only applied for non-evaluable arteries on CTCA (14%).
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using an 82Rb PET/CT hybrid system. Sato et al.45 showed that
adding SPECT information in non-evaluable arteries on CTCA
improved particularly specificity and PPV of the latter techniques
significantly (from 80 to 92%, and from 69 to 85%, respectively).
Notably, the majority of non-evaluable severely calcified vessels
in the left anterior descending artery were positive on stress
nuclear MPI, whereas the majority of non-evaluable vessels
with motion artefacts in the RCA were negative. One of the
largest, recently published studies included 107 patients
undergoing hybrid 15O–H2O PET/64slice-CTCA.
46 In this
study, haemodynamic significance of ICA stenoses was con-
firmed in 18 of 40 patients with FFR providing a more compre-
hensive gold standard. Consequently, the use of PET/CTCA
increased the PPV significantly from 76 to 96% compared with
CTCA alone.
However, a number of limitations apply to the aforementioned
studies, including the limited number of patients, the variety of
hybrid systems used, and the lack of a uniform gold standard.
Three studies have specifically addressed the incremental value
of hybrid cardiac imaging over the side-by-side analysis of
CTCA and myocardial perfusion images (Table 2). In the first
report of 38 patients with perfusion defects on SPECT, the
number of lesions with equivocal haemodynamic relevance was
significantly reduced using SPECT/CTCA fusion compared with
the side-by-side analysis.47 Among these equivocal lesions the
hybrid approach confirmed haemodynamic significance in 35%
and excluded it in 25%. This added clinical value could be
observed in 29% of all patients, and was particularly common
in patients with multivessel disease and intermediate severity ste-
noses or in patients with diseased side branches. Santana et al.48
showed a significantly higher diagnostic performance for fused
SPECT/CTCA imaging compared with SPECT alone (P, 0.001)
and to the side-by-side analysis of SPECT and CTCA (P ¼
0.007) for the diagnosis of obstructive CAD on ICA. Interestingly,
this improved diagnostic performance was mainly a result of a
higher sensitivity in patients with multivessel disease. A recent
study implementing motion-frozen SPECT data and CTCA-guided
SPECT contour and territory adjustments found that the
improved diagnostic value of hybrid imaging was mainly driven
by higher diagnostic indices in LCX and RCA territories.49
Hence, hybrid cardiac imaging may facilitate the identification
of haemodynamically significant coronary artery stenoses and
thereby guide clinicians on the appropriate method of revascular-
ization. Moreover, in intermediate stenoses, a hybrid study may
accurately confirm or rule out their haemodynamic significance
and thereby reduce the number of potentially unnecessary
stent implantations, a key cost driver in cardiovascular medicine.
A recent study including .500 patients has also documented the
prognostic value of hybrid imaging.38 In this study, CTCA pro-
vided independent prognostic information over SPECT alone.
Most importantly, in patients with a normal SPECT study, an
abnormal CTCA scan was associated with a higher rate of the
combined endpoint, and therefore warrants more aggressive
risk factor modification. These observations lend further
support to the notion that stable CAD patients should undergo
a comprehensive assessment of both myocardial perfusion and
coronary morphology in order to fully apprehend their coronary
risk and assist in the choice of the most appropriate treatment
strategy. Nonetheless, it should be noted that evidence to
support these assumptions is still scarce and just beginning to
accrue. Further studies are needed to document an effect of
hybrid imaging on treatment strategies, and to assess whether
changes in treatment based on hybrid imaging may have an
impact on the patients’ prognosis. Results of ongoing prospective
multicentre trials, such as SPARC, EVINCI and PROMISE, are
therefore eagerly awaited and will hopefully shed more light
into the future of cardiac hybrid imaging.50,51
Table 3 Incremental clinical value of hybrid imaging
in the diagnosis of coronary artery disease
Improved diagnostic performance to detect CAD compared with
SPECT of CTCA alone
Allows to identify flow-limiting coronary lesions (‘culprit lesions’)
requiring revascularization (particularly in the RCA- and LCX-
territory and with multivessel disease)
Adds diagnostic information in approximately one-third of patients
Provides independent prognostic information through combination of
morphological and functional criteria
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Table 2 Incremental clinical value of fused hybrid imaging compared to the side-by-side analysis
Author Hybrid system Patient population Incremental value of fused hybrid imaging
Gaemperli
et al.47
SPECT/64-slice CTCA and 3D image fusion 38 patients with ≥1
SPECT defects
Modification of initial interpretation in 29% of patients
In equivocal lesions, haemodynamic relevance could be
confirmed in 35% and excluded in 25%
Santana et al.48 16- and 64-slice CTCA and MPI (SPECT or
82Rb PET)
50 patients with
suspected CAD
Modification of initial interpretation in 28% of patients
Trend towards increased sensitivity (by 17%) in patients with
multivessel disease
Slomka et al.49 Motion-frozen SPECT/64-slice CTCA
(automatic coregistration)
35 patients with
suspected CAD
Improved diagnostic performance in RCA- and
LCX-territories
SPECT denotes single photon emission computed tomography; CTCA, CT coronary angiography; MPI, myocardial perfusion imaging; PET, positron emission tomography; CAD,
coronary artery disease.
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Figure 4 Proposed clinical algorithm for the use of hybrid imaging in the diagnosis of coronary artery disease. *A second non-invasive test
may be performed if the first test was inconclusive or equivocal. **Myocardial perfusions imaging may be performed in high pre-test probability
patients to localize ischaemia. CTCA denotes CT coronary angiography; MPI, myocardial perfusions imaging; RF, risk factor; ICA, invasive cor-
onary angiography; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting. Adapted from Flotats et al.55
Figure 5 Eighty-six-year-old patient with increasing angina at rest. The invasive coronary angiography (A) demonstrates a left dominance with
severely calcified vessels. The left anterior descending coronary artery shows a proximal 50–70% stenosis and a distal long functional occlusion
(solid blue arrows). The intermediary branch is functionally occluded. The left circumflex artery shows a proximal 50% stenosis. On single
photon emission computed tomography (B), a large inferior (small white arrows) and a faint anterolateral ischaemia (solid black arrows)
can be observed. The hybrid single photon emission computed tomography/computed tomography coronary angiography reconstructions
(C ) highlight the dominance of the left anterior descending artery (solid blue arrows), which turns at the apex to supply the majority of the
inferior wall and is responsible for the large ischaemia (small white arrows). Additionally, the anterolateral ischaemia can be assigned to the
intermediary branch (solid black arrows).
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Role of coronary artery calcium
scoring for hybrid imaging
A large body of evidence has established coronary artery calcium
scoring (CACS) as a strong predictor of cardiovascular events in
asymptomatic subjects.52 Besides its prognostic value, the CACS
can also be used for diagnostic purposes in symptomatic patients.
A number of studies have addressed the added diagnostic and
prognostic value of CACS combined with MPI, due to the relative
ease to obtain CACS images (no contrast injection and low overall
radiation exposure). This approach is further promoted by the
increasing availability of hybrid scanners integrating low- or
high-end CT devices with SPECT cameras). In a recent study by
Schepis et al.,53 77 symptomatic patients with intermediate coron-
ary risk (based on a 10-year Framingham risk for death or non-fatal
MI of 10–20%) underwent SPECT, CACS, and ICA for suspected
CAD. The added use of CACS (at a cut-off of 709 Agatston units)
increased the sensitivity of SPECT from 76 to 86% and NPV from
76 to 83%. Thus, adding CACS to SPECT may allow detecting
patients with extensive multivessel disease, which, despite
normal perfusion on SPECT, may have a paradoxical high long-
term coronary risk.54
Schenker et al.54 first documented an added and independent
prognostic value of CACS combined with MPI. In a prospective
follow-up study including 695 consecutive patients with intermedi-
ate clinical risk undergoing CACS and 82Rb perfusion PET, the
authors observed a stepwise increase in death and MI rates with
increasing CACS in patients with and without ischaemia. Among
patients with normal perfusion, the annualized event rate in
patients with a CACS of 0 was lower than in those with a CAC
score ≥1000 (2.6 vs. 12.3%, respectively). Likewise, in patients
with ischaemia on PET, the annualized event rate in those with a
CACS of 0 was lower than among patients with a CAC score
≥1000 (8.2 vs. 22.1%).
How to implement cardiac hybrid
imaging into current algorithms
Table 3 summarizes the most important clinical aspects of cardiac
hybrid imaging. Current evidence described above suggests that
hybrid imaging may be particularly useful in the following sub-
groups of patients: Patients with multivessel disease or perfusion
defects involving the inferior and lateral wall, and patients in
which either CTCA or MPI yields inconclusive or equivocal
results. In the latter group, the second test is performed to
exclude or confirm a potentially pathological finding in the first
test according to a protocol of ‘serial testing’. The second test
therefore plays the role of an additional gatekeeper of ICA and
fusion of images is performed ‘on-the-go’ (Figure 4). Although in
the majority of cases, separate analysis of data sets largely serves
the purpose of gatekeeping, fusion of images is recommended as
clinical information can be enhanced in almost one-third of patients
(Table 3). In the former group, hybrid imaging is performed to allo-
cate perfusion defects to their corresponding coronary artery and
guide revascularization strategies. Often, patients are referred after
diagnostic ICA, in which the culprit lesion is unclear and the
difficult anatomy of the lesions (calcified long or bifurcated
lesions, chronic total occlusions, tortuous vessels) is a deterrent
to ad hoc PCI (Figure 5). This approach allows to confirm the
haemodynamic significance of a given lesion before embarking in
tedious and potentially harmful revascularization attempts, and
provides a platform for multidisciplinary coronary teams including
an interventional cardiologist and a cardiac surgeon to discuss the
most appropriate treatment strategy (medical conservative vs. per-
cutaneous vs. surgical revascularization).
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Table 4 Estimated effective radiation dose from
cardiac diagnostic imaging
Protocol Injected
activity
(MBq)a
Effective
dose (mSv)
99mTc sestamibi 1-day stress/rest 350/1000 11.3
99mTc sestamibi 2-day stress/rest 950/950 15.7
99mTc tetrofosmin 1-day stress/
rest
320/960 9.3
99mTc tetrofosmin 2-day stress/
rest
950/950 12.8
201Tl stress/redistribution 130 22.0
201Tl stress/reinjection 55/110 31.4
82Rb stress/rest72 1850/1850 4.6
13N–NH3 stress/rest 550/550 2.4
15O–H2O stress/rest 1100/1100 2.5
18F-fluorodeoxyglucose (viability) 350 7.0
CAC-scan (prospective
ECG-triggering)73
1.0
CAC-scan (retrospective
ECG-triggering)73
3.0
4-slice CTCA (without tube
current modulation)
6.7–13.0
4-slice CTCA (with tube current
modulation)
2.5–6.2
16-slice CTCA (without tube
current modulation)
4.9–20.6
16-slice CTCA (with tube current
modulation)
4.3–8.1
64-slice CTCA (without tube
current modulation)
8.0–21.4
64-slice CTCA (with tube current
modulation)
7.0–14.0
64-slice CTCA (prospective
ECG-triggering)30
2.1
320-slice CTCA (prospective
ECG-triggering)74
6.8
2×128-slice (dual source), high
pitch spiral-CTCA58
0.9
Diagnostic coronary angiography 2.3–22.7
Adapted from Einstein et al.56
aEffective radiation doses are estimated using ICRP publication 60 tissue weighting
factors.75
CAC denotes coronary artery calcium; CTCA, CT coronary angiography; ECG,
electrocardiogram.
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Recently, a joint position statement by the European Association
of Nuclear Medicine (EANM), the European Society of Cardiac Radi-
ology (ESCR), and the European Council of Nuclear Cardiology
(ECNC) have given recommendations on the appropriate use of
cardiac hybrid imaging.55 The statement supports its use in patients
with an intermediate pre-test probability of CAD and acknowledges
its potential as a promising cardiac non-invasive imaging tool. It is also
noted, however, that the clinical impact and the incremental value of
hybrid imaging need to be evaluated in larger cohorts and multicen-
tre investigations. As mentioned above, data are still lacking on the
impact of hybrid imaging on management strategies, cardiovascular
outcomes, and cost-effectiveness.
Radiation exposure
Positron emission tomography, SPECT, and CT are diagnostic
modalities that use ionizing radiation to generate images of ana-
tomical structures. The widely accepted ‘Linear-No-Threshold’
(LNT)-theory describes a linear relationship between radiation
dose and radiation-induced stochastic effects (particularly cancer
risk). In fact, depending on image modality, choice of radionuclide,
and protocol, radiation exposure from medical imaging may vary
considerably, and early studies with 64-slice CTCA report total
effective radiation doses of up to 21.4 mSv.56 However, improve-
ments in image acquisition protocols, particularly the introduction
of ECG-driven tube current modulation, body-mass-index-adapted
tube voltage modulation, and prospective ECG-triggered sequen-
tial scanning have achieved 30–90% reductions in patient radi-
ation exposure.30,57 The most recent high-pitch scanning
protocols using dual-source CT scanners have even lowered
doses into the sub-milli-Sievert range (Table 4).58
Similarly, myocardial perfusion SPECT using 102Thallium may
reach effective radiation doses up to 20–30 mSv. Shorter-lived
perfusion tracers based on 99mTechnetium (99mTc) allow much
lower radiation exposure in the range of 9.3 mSv for a full 1-day
stress/rest study. The current introduction of solid-state detectors
based on cadmium–zinc–telluride alloy may allow to further
reduce radiation exposure by means of a higher detector sensi-
tivity and improved energy resolution.59 Moreover, some of the
currently used cyclotron-dependent perfusions tracers for PET
imaging (i.e. 15O–H2O and
13N–NH3) are associated with even
lower radiation doses and may therefore be particularly suitable
for hybrid imaging (Table 4).42,46
Recent years have witnessed an explosion in the use of medical
imaging procedures which has subsequently shifted the focus on
aspects of patient safety and radiation risks.60 Current efforts are
directed towards reducing radiation exposure from medical
imaging while maintaining a high level of image quality and diagnos-
tic performance. Particularly, in the field of cardiac non-invasive
imaging, impressive reductions in patient radiation exposure have
been achieved through optimized image acquisition protocols
and a more advanced generation of scanners thereby promoting
the use of hybrid technologies in clinical practice.30 In fact, a
recent report has documented the feasibility of stress-only
SPECT/CTCA hybrid studies with a cumulative radiation dose of
5.4 mSv.61
Future perspectives—hybrid
imaging using molecular targets
Radionuclide imaging is increasingly contributing to the develop-
ment of imaging strategies which go beyond the assessment of
myocardial perfusion, towards characterization of molecular
events on the tissue level. Cardiovascular molecular imaging aims
at the visualization of specific molecules and pathways that
precede or underlie changes in morphology, physiology, and func-
tion. Examples are the use of neuronal imaging to identify subjects
Figure 6 Fusion beyond images. Possible organization of joint multi-disciplinary diagnostic services. Reprinted from Fraser et al.71 with permission
of Oxford University Press.
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at risk for ventricular arrhythmia,62,63 the development of com-
pounds targeting plaque vulnerability before rupture and sub-
sequent myocardial infarction,64,65 and the targeting of
biomechanisms which precede left ventricular remodelling and
heart failure development.66,67 Additionally, molecular imaging
has great potential to facilitate the discovery and development of
novel therapies through improved target identification and
implementation of more efficient endpoints, as well as visualization
of cellular and subcellular target structures. Examples are the
development of reporter gene imaging techniques,68 and the
implementation of cell labelling for imaging of engraftment after
transplantation.69 This need to visualize small amounts of
molecular-targeted compounds in small target areas will not only
drive advances in the imaging sciences such as in instrumentation,
reconstruction algorithms and probe design in order to improve
the detection sensitivity, molecular specificity, and translational
potential. It also provides a strong rationale for hybrid imaging
approaches, where the nuclear imaging component is used for
molecular targeting and the CT is used for localization of the mol-
ecular signal.70
Conclusions
Through integration and spatial co-localization of morphological
and functional information, hybrid imaging appears to offer
superior diagnostic and prognostic information compared with
stand-alone or side-by-side interpretation of data sets. Particularly
in patients with multivessel disease and/or perfusion defects in
inferolateral myocardial territories, the hybrid approach allows
identification of flow-limiting coronary lesions and thereby pro-
vides useful information for the planning of revascularization pro-
cedures. However, the clinical impact and incremental value of
integrated imaging need to be evaluated and confirmed in larger
cohorts and multicentre investigations. Furthermore, integration
of the detailed anatomical information from CTCA with the high
molecular sensitivity inherent with SPECT and PET may be
useful to evaluate targeted molecular and cellular abnormalities
in the future. It is foreseeable that the appropriate use of alterna-
tive and complementary tests will require their integration into
joint clinical diagnostic services where experts in all methods col-
laborate (Figure 6).71 This process will be supported by a shift from
specializing in a particular technique that is applied by cross-
sectional imaging to multiple organs, to an organ or system-based
approach where the diagnostic expert is more concerned with
function, the integration of results into clinical decision-making,
and the impact of diagnostic imaging on clinical outcomes.
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